Use of fatigue assessment scale and small fiber neuropathy screening list in Japanese patients with sarcoidosis
Keywords:
Fatigue Assessment Scale (FAS), Small fiber neuropathy, SF-36, Health-related quality of life, SarcoidosisAbstract
Background: The Fatigue Assessment Scale (FAS) and Small Fiber Neuropathy Screening List (SFNSL) are widely used in Western countries to investigate symptoms associated with fatigue and small fiber neuropathy (SFN). However, few studies have used these patient-reported outcome measures (PROMs) in Japan.
Methods: This was a cross-sectional and longitudinal study at an outpatient clinic in a community teaching hospital in Japan. Participants completed the FAS, SFNSL, and Short Form-36. Clinical parameters, including angiotensin-converting enzyme (ACE) and soluble interleukin-2 receptor (sIL2R), were derived from the medical records of the patients.
Results: The study population included 55 patients (29 males; 26 females; mean age: 59±15 years; median disease duration: 5.0 years). Eleven patients received a systemic corticosteroid. The mean FAS score was 22.7±8.2; 27 patients (49.1%) and five patients (9.1%) indicated fatigue (score: ≥22) and extreme fatigue (score: ≥35), respectively. The mean SFNSL score was 13.8±14.3; 23 patients (41.8%) and two patients (3.6%) indicated probable/highly probable SFN (score: 11–48) and SFN (score: ≥49), respectively. The FAS score exhibited strong correlations with physical function, vitality, and mental health of Short Form-36. The SFNSL score exhibited strong correlations with bodily pain and vitality. Of the 55 patients, 45 completed the 1-year follow-up. There were no significant changes noted in the FAS score (mean: 0.04, 95% confidence interval: −1.29–1.38) and SFNSL score (mean: 0.31, 95% confidence interval: −2.12–2.74) during the follow-up. Within-subject changes in FAS and SFNSL scores showed moderate correlations with those of physical function and general health, respectively. There was no significant relationship between FAS or SFNSL score and ACE or sIL2R values at baseline and within-subject changes in these parameters during the follow-up.
Conclusions: Approximately half of the patients suffered from fatigue or SFN. These nonspecific symptoms have a great effect on quality of life.
References
Hattori T, Konno S, Shijubo N, et al. Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan. Sci Rep 2018; 8: 9440.
Judson MA, Costabel U, Drent M, et al, Organ Assessment Instrument Investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 19-27.
de Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15: 499-506.
De Vries J., Lower E E, Drent M. Quality of life in sarcoidosis: assessment and management. Seminars Respir Crit Care Med 2010; 31: 485-93.
Hoitsma E, Drent M, Verstraete E, et al. Abnormal warm and cold sensation thresholds suggestive of small-fibre neuropathy in sarcoidosis, Clin Neurophysiol 2003; 114: 2326-33.
Bakkers M, Merkies I S, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73: 1142-8.
Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15: 201-6.
Lower EE, Sturdivant M, Baughman RP. Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36: 254-60.
Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber C G, Drent M. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 33-9.
Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003; 54: 345-52.
De Vries J, Michielsen HJ, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9: 279-91.
Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med 2011; 105: 95-100.
the Japan Society of Sarcoidosis and Other Granulomatous Disorders (JSSOG) diagnostic standard and guideline for sarcoidosis-2015 [Japanese], http://jssog.com/www/top/shindan/shindan2-1new.html. [Accessed 25 June 2018]
Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ 1961; 2: 1165-72.
Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-6.
de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105: 1388-95.
Michielsen HJ, de Vries J, Drent M, Peros-Golubicic T. Psychometric qualities of the Fatigue Assessment Scale in Croatian sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 133-8.
Saketkoo LA, Russell AM, Jensen K, et al. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel). 2021; 11: 1089.
http://www.wasog .org/educationresearch/questionnaires.html [Accessed 25 June 2019]
Fukuhara S, Suzukamo Y. Health-related quality of life-SF8 and SF36. J Clin Exp Med 2005; 213: 133-6. (SF-36v2TM Health Survey© 1992, 2000, 2003 Quality Metric Incorporated, Medical Outcomes Trust and Shunichi Fukuhara. All rights reserved. SF-36® is a registered trademark of Medical Outcomes Trust. (SF-36v2 Standard, Japanese)
Suzukamo Y, Fukuhara S, Green J, Kosinski M, Gandek B, Ware JE. Validation testing of a three-component model of Short Form-36 scores. J Clin Epidemiol 2011; 64: 301-8.
Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health related quality of life of persons with sarcoidosis. Chest 2004; 125: 997-1004.
Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med 1998; 53: 53-60.
De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 127-36.
Hinz A, Fleischer M, Brähler E, Wirtz H, Bosse-Henck A. Fatigue in patients with sarcoidosis, compared with the general population. Gen Hosp Psychiatry 2011; 33:462-8.
Kıter G, Müsellim B, Cetinkaya E, et al; Sarcoidosis Working Group of Turkish Thoracic Society. Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis). Tuberk Toraks 2011; 59: 248-58.
Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38: 628-34.
Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255-63.
Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31: 372-9.
Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130: 989-94.
Drent M, Marcellis R, Lenssen A, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 117-28.
Korenromp IHE, Heijnen CJ, Vogels OJM, van den Bosch JMM, Grutters JC. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011; 140: 441-7.
Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M. Predictors of fatigue in sarcoidosis: The value of exercise testing. Respir Med 2016; 116: 49-54.
Møller J, Hilberg O, Bendstrup E. Fatigue in patients with sarcoidosis in Denmark. Lung 2023; 201: 103-10.
Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012; 18: 1430-6.
Drent M, Strookappe B, Hoitsma E, De Vries J. Consequences of sarcoidosis. Clin Chest Med 2015; 36: 727-37.
Voortman M, Hendriks CMR, Elfferich MDP, et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung 2019; 197: 155-61.
Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 2017; 126: 135-8.
Voortman M, Fritz D, Vogels OJM, et al. Small fiber neuropathy: a disabling and underrecognized syndrome. Curr Opin Pulm Med 2017; 23: 447-57.
Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respir Med 2018; 138S: S24-S30.
Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res 2018; 4: 00141-2018.
Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e26-e51.
Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med 2015; 191: 786-95.
Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013; 68: 57-65.
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
